Followers | 177 |
Posts | 24457 |
Boards Moderated | 13 |
Alias Born | 04/03/2002 |
Monday, June 14, 2021 10:38:21 AM
From the company website:
IkT-148009 for Parkinson’s Disease
Our lead small-molecule product candidate, IkT-148009, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that targets underlying disease mechanisms to halt the progression and reverse functional loss of Parkinson’s disease in the brain and the GI complications of Parkinson’s disease. We believe that IkT-148009 is the only disease-modifying drug in development for Parkinson’s disease that is focused on a clinically validated target and that IkT-148009 has the potential to be the first disease-modifying therapy for Parkinson’s disease that blocks a checkpoint on the pathway that drives Parkinson’s disease progression.
ABOUT IKT-148009
First-in-class Therapy to Reverse the Course of Parkinson’s Disease
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in the brain and GI tract in animal models using IkT-148009, we submitted two Investigational New Drug (IND) applications in February, 2019, to begin clinical development in multiple classes of Parkinson’s patients. Clinical development should proceed through 2024.
Recent IKT News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/09/2024 06:41:37 PM
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:59:02 PM
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers • GlobeNewswire Inc. • 02/07/2024 12:55:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:49:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:09:53 PM
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib • GlobeNewswire Inc. • 01/29/2024 02:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:31:03 PM
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli • GlobeNewswire Inc. • 01/16/2024 09:05:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 12/04/2023 01:35:00 PM
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 11/14/2023 09:30:06 PM
- Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 02:28:32 PM
- Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 10/16/2023 09:24:04 PM
- Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment • GlobeNewswire Inc. • 10/16/2023 11:00:27 AM
- Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy • GlobeNewswire Inc. • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 03:23:58 PM
- Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib • PR Newswire (US) • 08/24/2023 12:30:00 PM
- Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders • PR Newswire (US) • 08/22/2023 12:05:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM